Bullous pemphigoid in a patient with psoriasis after mRNA COVID-19 vaccination

被引：0

作者：

Merilleno, Arbie Sofia P. ^{[1
]}

Quizon, Mae R. ^{[1
]}

Legaspi, Kristine Natalee M. ^{[2
]}

机构：

[1] Rizal Med Ctr, Dept Dermatol, Pasig Blvd, Pasig 1600, Metro Manila, Philippines

[2] St Gabriel Med Ctr, Dept Dermatol, Aklan, Philippines

来源：

JEADV CLINICAL PRACTICE | 2023年 / 2卷 / 01期

关键词：

bullous pemphigoid; case report; mRNA COVID-19 vaccination; Pfizer; psoriasis;

D O I：

10.1002/jvc2.88

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Bullous pemphigoid and psoriasis are two well-characterised chronic autoimmune diseases that may be triggered by drugs, infections or vaccines. The coexistence of the two is a rare event but is more extraordinary if incited by messenger RNA (mRNA) COVID-19 vaccination. A 62-year-old Filipino male experiencing a flare-up of his long-standing psoriasis vulgaris presented with new onset tense blisters on the legs 2 days after his first booster dose of mRNA (Pfizer-BioNTech) vaccination. The clinical, skin punch biopsy, direct immunofluorescence and enzyme-linked immunosorbent assay were consistent with bullous pemphigoid. Complete resolution of the vesicles and bullae with no new lesions and flattening of psoriasis plaques were observed after 1 month of treatment of systemic corticosteroids and corticosteroid-sparing agents. An association may exist between bullous pemphigoid development and mRNA COVID-19 vaccination.

引用

页码：152 / 155

页数：4

共 15 条

[1]

Moro F., Fania L., Sinagra J.L.M., Salemme A., Di Zenzo G., Bullous pemphigoid: trigger and predisposing factors, Biomolecules, 10, 10, (2020)

[2]

Huang Y.-W., Tsai T.-F., Exacerbation of psoriasis following COVID-19 vaccination: report from a single center, Front Med, 8, (2021)

[3]

Zhang L.-M., Wu J., Xiao T., Jin G.-Y., Li J.-H., Geng L., Et al., Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study, Eur J Dermatol, 23, 1, pp. 94-98, (2013)

[4]

Ohata C., Ishii N., Koga H., Fukuda S., Tateishi C., Tsuruta D., Et al., Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases, J Am Acad Dermatol, 73, 1, pp. 50-55, (2015)

[5]

Donnelly K.M., Ferris L.K., Kaffenberger J.A., A systematic review of concomitant bullous pemphigoid and psoriasis, J Psoriasis Psoriatic Arthritis, 1, 4, pp. 150-158, (2016)

[6]

Tabatabaei-Panah P.S., Moravvej H., Aghaei S., Akbari M., Rajabi S., Kia A., Et al., TH17/IL23 cytokine gene polymorphisms in bullous pemphigoid, Mol Genet Genomic Med, 8, 12, (2020)

[7]

Freeman E.E., Sun Q., McMahon D.E., Singh R., Fathy R., Tyagi A., Et al., Skin reactions to COVID-19 vaccines: an American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type, J Am Acad Dermatol, 86, 4, pp. e165-e167, (2022)

[8]

Tomayko M.M., Damsky W., Fathy R., McMahon D.E., Turner N., Valentin M.N., Et al., Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination, J Allergy Clin Immunol, 148, 3, pp. 750-751, (2021)

[9]

Garcia-Montero C., Fraile-Martinez O., Bravo C., Torres-Carranza D., Sanchez-Trujillo L., Gomez-Lahoz A.M., Et al., An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times, Vaccines, 9, 5, (2021)

[10]

Gambichler T., Boms S., Susok L., Dickel H., Finis C., Abu Rached N., Et al., Cutaneous findings following COVID-19 vaccination: review of world literature and own experience, J Eur Acad Dermatol Venereol, 36, 2, pp. 172-180, (2021)

← 1 2 →